Supporting the lifestyle modification and treatment of type 2 diabetes for people with severe mental illness

Authors

  • J Pendlebury
  • RIG Holt

DOI:

https://doi.org/10.1002/edn.110

Keywords:

Severe mental illness, schizophrenia, antipsychotic, diabetes

Abstract

Abstract

This review describes the association between diabetes and the two main severe mental illnesses (SMIs), schizophrenia and bipolar illness, which have been recognised for over a century. It also explains how lifestyle modification can improve outcomes. People with SMI have an increased prevalence of other metabolic comorbidities. The increase in diabetes and metabolic syndrome is a predictor of cardiovascular disease, which is the commonest cause of death in people with SMI (accounting for up to 60% of all deaths in these people). Factors contributing to risk of disease are the same in people with SMI as in the general population, but lifestyle is probably most important because this is potentially amenable to modification. Poverty, urbanisation, poor diet and physical inactivity are key risk factors for diabetes that occur more frequently in people with SMI. SMI contributes further to diabetes risk as illustrated by studies of drug-naïve first-episode patients. Antipsychotic medications have been implicated in diabetes development. The high prevalence of diabetes has a number of clinical implications for care. First, we need to screen for diabetes, as recommended by national bodies including the National Institute for Health and Clinical Excellence (NICE) and the American Diabetes Association. Secondly, we need to implement strategies to reduce the risk of diabetes. The Salford Weight Management Clinic, established in May 2000, has shown that lifestyle modification is possible in SMI. Finally, strategies should be developed to manage the health of people with SMI who develop diabetes.

Downloads

Download data is not yet available.

References

Maudsley H. The Pathology of Mind, 3rd edn. London: Macmillan, 1879.

Holt RI, Bushe C, Citrome L, Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol 2005; 19: 56–65.

Jablensky A. Epidemiology of schizo-phrenia: the global burden of dis-ease and disability. Eur Arch Psych Cub?, Neurosci 2000; 250: 274–285.

Citrome L. Metabolic syndrome and cardiovascular disease. J Psycho-pharmacol 2005; 19: 84–93.

McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizo-phrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19–32.

Brown S, Inskip H, Barraclough B, Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212–217.

Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy life-style of people with schizophrenia. Psy chol Med 1999; 29: 697–701.

McC re adie R, Macdonald E, Blacklock C, et al. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. Br Med J1998; 317: 784–785.

Gough SC, O'Donovan MC. Clus-tering of metabolic comorbidity in schizophrenia: a genetic contribu-tion?JPsychopharmacol 2005; 19: 47–55.

Ryan MC, Collins P, Thakore JR, Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284–289.

Thakore JH, Mann JN, Vlahos I, , et aL Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Rel Metab Disord 2002; 26: 137–141.

Dinan TG. Stress and the genesis of diabetes mellitus in schizophrenia. Br J Psychiatry Suppl 2004; 47: 72–75.

Thonnard-Neumann E. Phenothia-zines and diabetes in hospitalized women. Am J Psychiatry 1968; 124: 978–982.

Hiles BW. Hyperglycaemia and glu-cosuria following chlorpromazine therapy. JAMA 1956; 162: 1651.

Jin H, Meyer JM, Jeste DV, Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002; 14: 59–64.

Holt RI, Peveler RC. Antipsychotic drugs and diabetes - an application of the Austin Bradford Hill criteria. Diabetolngia 2006; 49: 1467–1476.

Citrome LL, Holt RI, Zachry WM, et al. Risk of treatment-emergent diabetes mellitus in patients receiv-ing antipsychotics. Ann Pharmacother 2007; 41: 1593–1603.

Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006; 8: 125–135.

Subramaniam M, Chong SA, Pek E, Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003; 48: 345–347.

Voruganti LP, Punthakee Z, Van Lieshout, RJ, et al. Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study. Schizophr Res 2007; 96: 215–222.

Citrome L, Yeomans D. Do guide-lines for severe mental illness pro-mote physical health and well-being? J Psychopharmacol 2005; 19: 102–109.

'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus sum-mary. Br J Psychiatry Suppl 2004; 47:

Taylor D, Young C, Esop R, , et aL Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004; 185: 152–156.

Holt RIG, Peveler RC. The high prevalence of undiagnosed meta-bolic complications in people with severe mental illness. Diabetic Med 2007; 24 (Suppl 1): P251

Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 dia-betes mellitus by changes in lifestyle among subjects with impaired glu-cose tolerance. N Engl J Med 2001; 344: 1343–1350.

Pan XR, Li GW, Hu YET, , et aL Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537–544.

Knowler WC, Barrett-Connor E, Fowler SE, et at, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002; 346: 393–403.

Diabetes Prevention Program Research Group. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Ada Psychiatr Scand 2007; 115: 286–294.

Menza M, Vreeland B, Minsky S, et al. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight con-trol program. J Clin Psychiatry 2004; 65: 471–477.

Downloads

Published

2008-09-01

How to Cite

Pendlebury, J., & Holt, R. (2008). Supporting the lifestyle modification and treatment of type 2 diabetes for people with severe mental illness. International Diabetes Nursing, 5(2), 58–63. https://doi.org/10.1002/edn.110

Issue

Section

Review Article